Bio-Techne (TECH) Aktie Kurs
Bio-Techne Kurs
Intäkterna har vuxit med 9,3 % per år under de senaste 19 åren till 1,22 Mrd USD. Vinst per aktie har vuxit med 4,1 % per år under de senaste 19 åren. Bio-Technes nettovinstmarginal ligger på 15,0 %, ned från 24,6 % för några år sedan. Bio-Techne har för närvarande en direktavkastning på cirka 0,44 %. Utdelningsandelen är omkring 40 % av vinsten. Utdelningen har vuxit med 9,5 % per år under de senaste 18 åren. Analytikernas mediankursmål är 73,00 USD, vilket är över nuvarande kurs med 0,5 %. Av 20 analytiker ger 6 köpråd — den samlade bedömningen är Behåll.
Bio-Techne aktiekurs
Hämta dessa data via Eulerpool API
100 000 anrop/mån gratis · inget kreditkort
Bio-Techne affärsmodell och aktieanalys
Vanliga frågor om Bio-Techne-aktien
Bio-Techne Corp's business model revolves around providing innovative life science tools and solutions to researchers worldwide. The company focuses on developing and manufacturing high-quality reagents, assays, and instruments used in biomedical research, clinical diagnostics, and pharmaceutical development. With a diverse portfolio, Bio-Techne offers products for gene expression analysis, protein analysis, cell imaging, and stem cell research. Their advanced technologies and expertise enable scientists to accelerate discoveries and enhance their understanding of diseases, ultimately aiding in the development of new therapies. Bio-Techne Corp strives to be at the forefront of scientific advancements by continually investing in research and development initiatives.
Bio-Techne Corp primarily operates in the biotechnology and life sciences industries. Its extensive product portfolio includes cutting-edge solutions for research and diagnostics, spanning the fields of pharmaceuticals, clinical applications, bioprocessing, and academia. With a focus on developing innovative technologies, Bio-Techne Corp delivers products and services that support advancements in areas such as cancer research, stem cell research, immunology, neuroscience, and genetic analysis. As a leading player in these sectors, Bio-Techne Corp continues to make significant contributions to the scientific community and drive progress in the biotechnology field.
Some of the main competitors of Bio-Techne Corp in the market include Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies.
Bio-Techne Corp, formerly known as Techne Corporation, is a leading global life sciences company. Established in 1976, Bio-Techne has a rich history of innovation and scientific discovery. The company develops and manufactures a wide range of cutting-edge products and solutions for the biotechnology and clinical research industries. With a strong focus on research and development, Bio-Techne has consistently brought forth groundbreaking technologies and advanced tools, revolutionizing the understanding and treatment of diseases. Today, Bio-Techne Corp remains at the forefront of the life sciences industry, delivering high-quality products and driving advancements in scientific research worldwide.
Bio-Techne Corp has achieved several significant milestones. The company has successfully expanded its product portfolio, offering a wide range of innovative solutions in life sciences research and diagnostics. Bio-Techne Corp has also witnessed strong financial performance, consistently delivering impressive revenue growth over the years. Moreover, the company has made strategic acquisitions to enhance its capabilities and market presence. With a focus on advanced technologies and a commitment to innovation, Bio-Techne Corp continues to contribute to scientific advancements and improve healthcare outcomes globally.
Bio-Techne Corp is primarily present in various countries and regions worldwide. The company has a widespread global presence, with significant operations and a strong market presence in North America, Europe, and Asia-Pacific. This enables Bio-Techne Corp to serve a diverse customer base and tap into multiple international markets. Along with its headquarters in the United States, Bio-Techne Corp has strategic offices, production facilities, and distribution networks across key countries and regions globally. This expansive global footprint allows the company to effectively deliver its innovative biotechnology solutions and services to customers around the world.
Bio-Techne Corp is a leading global provider of life science products and solutions. The company values innovation, scientific excellence, and customer-centricity. Bio-Techne Corp's corporate philosophy revolves around advancing scientific discoveries and improving human health. With a strong commitment to research and development, Bio-Techne Corp focuses on providing cutting-edge tools and technologies to support the life science community. By fostering collaboration and investing in breakthrough technologies, the company aims to accelerate scientific progress and enable researchers to make significant contributions in the fields of genomics, proteomics, and cell biology. Overall, Bio-Techne Corp is dedicated to driving innovation and making a positive impact in the life science industry.
Analytiker sätter för närvarande ett genomsnittligt riktkurs på 65,78 USD för Bio-Techne-aktien (median: 73,00 USD), vilket innebär −9,5 % mot senaste kurs. Konsensus baseras på 20 analytikerbetyg.
20 analytiker betygsätter för närvarande Bio-Techne-aktien: 6 rekommenderar köp, 14 behåll och 0 sälj.
Omräknat till aktuell växelkurs handlas Bio-Techne-aktien till 65,21 EUR (72,67 USD).
Bio-Techne-aktien (TECH) är noterad på 4 börser, bland annat: NASDAQ (TECH), Frankfurt (TE1.F), München (TE1.MU), Düsseldorf (TE1.DU).
Bio-Techne Corp is a leading provider of innovative products for the biotechnology and clinical diagnostics industry. The company offers a wide range of products and services for protein research, cell analysis, microscopy, genomics, and clinical diagnostics. Protein research: Bio-Techne offers proteins, antibodies, reagents, and instruments for signal pathway research, protein expression, and function. Well-known brands in this field include R&D Systems, Novus Biologicals, Tocris, and ProteinSimple. Cell analysis: For cell analysis, Bio-Techne provides a wide range of products including cell analysis devices, reagents, and instruments for flow cytometry, cell culture, and microscopy. BioLegend is the leading brand for cell analysis products from Bio-Techne. Microscopy: Bio-Techne also offers a wide range of microscopy products for cell and tissue analysis. This includes endoscopes, cameras, microscopes, imaging software, and accessories. Brands in this field include Nikon Instruments, Zeiss, and Lumera. Genomics: Bio-Techne's genomics offering includes custom gene synthesis, antisense oligonucleotides, miRNA inhibitors, as well as PCR, qPCR, and sequencing kits and reagents. The company also provides comprehensive genomics services including analysis, sequencing, and data analysis. Clinical diagnostics: Bio-Techne provides solutions for clinical diagnostics, including IVD reagents, custom biomarker development and services, immunohistochemistry test systems, as well as devices and instruments for clinical sample submission. Brands in this field include R&D Systems, Novus Biologicals, and Exosome Diagnostics. Summary: Overall, Bio-Techne Corp offers a wide range of solutions for the biotechnology and clinical diagnostics industry. With its leading brands and extensive range of products and services, the company has established itself as a key player in this field. Through continuous product and service development and innovation, Bio-Techne is able to maintain its market share and further expand its business in various niche markets.
Omsättningen för Bio-Techne är 1,22 Mrd USD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.
Nettovinsterna för Bio-Techne är 181,86 M USD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.
Kurs-vinstkvoten (P/E) för Bio-Techne är för närvarande 62,73. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av Bio-Techne-aktien.
Kurs-försäljningskvoten (P/S) för Bio-Techne är för närvarande 9,39. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för Bio-Techne-aktien.
Eulerpool Quality Score för Bio-Techne är 4/10.
ISIN för Bio-Techne är US09073M1045. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.
WKN för Bio-Techne är A12ENG. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.
Tickern för Bio-Techne är TECH. Tickersymbolen används för att handla Bio-Techne-aktier på börsen.
Bio-Techne aktie
Bio-Techne Jämförbar grupp
Bio-Techne Ticker
Bio-Techne FIGI
Alla nyckeltal och djupgående analys av Bio-Techne
Vår aktieanalys av Bio-Techne-aktien innehåller viktiga finansiella nyckeltal som omsättning, vinst, P/E-tal, P/S-tal, EBIT samt information om utdelningen. Dessutom granskar vi aspekter såsom aktier, börsvärde, skulder, eget kapital och skuldförbindelser hos Bio-Techne. Om du söker mer detaljerad information om dessa ämnen erbjuder vi på våra undersidor ingående analyser: